Lisata Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Lisata TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 3.2% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 100.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 18.9% pro Jahr wachsen.

Wichtige Informationen

-3.2%

Wachstumsrate der Gewinne

18.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	100.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Jul 15

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

Mar 22

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Sep 15

Caladrius rallies on approval of merger, name change to Lisata Therapeutics

Sep 14

Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01

Aug 04

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

May 02

We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Jan 05

Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

May 09

Caladrius suspends CLBS119 COVID-19 study

Dec 14

Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Nov 30

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:LSTA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-22	N/A	N/A	2
12/31/2025	N/A	-26	N/A	N/A	2
12/31/2024	N/A	-22	N/A	N/A	2
9/30/2024	N/A	-21	-19	-19	N/A
6/30/2024	N/A	-21	-20	-20	N/A
3/31/2024	N/A	-20	-19	-19	N/A
12/31/2023	N/A	-21	-20	-20	N/A
9/30/2023	N/A	-21	-22	-22	N/A
6/30/2023	N/A	-54	-23	-23	N/A
3/31/2023	N/A	-56	-24	-24	N/A
12/31/2022	N/A	-54	-21	-21	N/A
9/30/2022	N/A	-55	-20	-19	N/A
6/30/2022	N/A	-25	-21	-20	N/A
3/31/2022	N/A	-24	-20	-20	N/A
12/31/2021	N/A	-27	-22	-22	N/A
9/30/2021	N/A	-26	-23	-23	N/A
6/30/2021	N/A	-25	-22	-22	N/A
3/31/2021	N/A	-12	-13	-13	N/A
12/31/2020	N/A	-8	-9	-9	N/A
9/30/2020	N/A	-8	-7	-7	N/A
6/30/2020	N/A	-7	-8	-8	N/A
3/31/2020	N/A	-19	-18	-18	N/A
12/31/2019	N/A	-19	-19	-19	N/A
9/30/2019	N/A	-18	-18	-18	N/A
6/30/2019	N/A	-17	-18	-18	N/A
3/31/2019	N/A	-16	-19	-19	N/A
12/31/2018	N/A	-16	-20	-20	N/A
9/30/2018	N/A	-17	-21	-21	N/A
6/30/2018	N/A	-17	N/A	-22	N/A
3/31/2018	N/A	-14	N/A	-17	N/A
12/31/2017	N/A	-16	N/A	-21	N/A
9/30/2017	N/A	-18	N/A	-20	N/A
6/30/2017	N/A	-20	N/A	-20	N/A
3/31/2017	-7	-26	N/A	-26	N/A
12/31/2016	N/A	-31	N/A	-24	N/A
9/30/2016	8	-59	N/A	-29	N/A
6/30/2016	13	-64	N/A	-32	N/A
3/31/2016	27	-74	N/A	-33	N/A
12/31/2015	22	-81	N/A	-39	N/A
9/30/2015	20	-59	N/A	-41	N/A
6/30/2015	18	-65	N/A	-46	N/A
3/31/2015	17	-60	N/A	-50	N/A
12/31/2014	18	-55	N/A	-47	N/A
9/30/2014	17	-56	N/A	-43	N/A
6/30/2014	16	-48	N/A	-36	N/A
3/31/2014	16	-44	N/A	-31	N/A
12/31/2013	15	-39	N/A	-27	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: LSTA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: LSTA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: LSTA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: LSTA wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: LSTA wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von LSTA in 3 Jahren voraussichtlich hoch sein wird

Lisata Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to US$8.00

Price target decreased to US$9.00

Consensus forecasts updated

Price target decreased to US$8.67

Analysts update estimates

Price target lowered to US$8.50

Recent updates

Lisata Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Lisata Therapeutics, Inc. Announces First Patient Treated in the Second-Line Cholangiocarcinoma Cohort of the BOLSTER Trial

Lisata Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Lisata Therapeutics, Inc. Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Lisata Therapeutics, Inc. Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in A Preclinical Model

Lisata Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Lisata Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

Lisata Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024

Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme

Lisata Therapeutics, Inc. Announces Completion of Enrollment in Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. Announces LSTA1 as A Treatment for Solid Tumor Cancers in Combination with Other Anti-Cancer Agents

New major risk - Revenue and earnings growth

Lisata Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Lisata Therapeutics, Inc. Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1

Lisata Therapeutics, Inc. Announces Outcome of Interim Futility Analysis for Its Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Lisata Therapeutics, Inc. Announces Retirement of Erkki Ruoslahti from Board of Directors

Lisata Therapeutics Announces Enhancements to Ongoing Phase 2B Ascend Trial of LSTA1

Less than half of directors are independent

Less than half of directors are independent

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Caladrius rallies on approval of merger, name change to Lisata Therapeutics

Nasdaq Grants Caladrius Biosciences an Extension Through February 13, 2023 to Evidence Compliance with the Bid Price Requirement

Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01

Caladrius Biosciences, Inc Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

Caladrius Biosciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in the Lancet Gastroenterology and Hepatology

Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA(R) in Coronary Microvascular Dysfunction

Caladrius Biosciences Inc. Announces IDMC Recommendation to Advance Clbs201 Trial for the Treatment of Diabetic Kidney Disease

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) entered into a definitive merger agreement to acquire Cend Therapeutics Inc. for $38.1 million.

Price target decreased to US$8.00

Insufficient new directors

Caladrius Biosciences, Inc. Treats First Patient in the Phase 1B Trial of CLBS201 for the Treatment of Diabetic Kidney Disease

Todd C. Girolamo Intent to Resign as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary of Caladrius Biosciences, Inc., Effective March 14, 2022

We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Price target decreased to US$9.00

Consensus forecasts updated

Caladrius Biosciences to Assess Its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease

Price target decreased to US$8.67

Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

Caladrius Biosciences, Inc. Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease

Analysts update estimates

Price target lowered to US$8.50

Caladrius Biosciences, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Caladrius Biosciences, Inc. announced that it has received $25 million in funding

Caladrius Biosciences, Inc. announced that it expects to receive $25 million in funding

New 90-day high: US$2.89

Caladrius Biosciences, Inc. Treats First Patient in the Phase 2B Freedom Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction

Caladrius suspends CLBS119 COVID-19 study

Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Price target raised to US$12.75

Caladrius Biosciences, Inc. Announces Executive Changes

New 90-day low: US$1.47

Caladrius Biosciences, Inc. Appoints Anne Whitaker to Board of Directors

Caladrius Biosciences, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: US$1.59

Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage

Insider recently bought US$100k worth of stock

New 90-day low - US$1.71

Caladrius Biosciences, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum